Drug Action
Temsirolimus is a protein kinase inhibitor.
PDF page 1080
Loading InternPractice…
Drug reference
Temsirolimus is a protein kinase inhibitor.
PDF page 1080
First-line treatment of advanced renal cell carcinoma | Treatment of relapsed or refractory mantle cell lymphoma ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature or local protocols)
PDF page 1080
NICE decisions ▶Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (August 2009) NICE TA178 Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced and/or metastatic renal cell carcinoma. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta178
PDF page 1080
→Appendix 1: temsirolimus
PDF page 1080
▶Common or very common Abscess. anaemia. anxiety. appetite decreased. arthralgia. asthenia. chest pain. chills . conjunctivitis. constipation. cough. cystitis. decreased leucocytes. dehydration. depression. diabetes mellitus. diarrhoea. dizziness. drowsiness. dyslipidaemia. dysphagia. dyspnoea. electrolyte imbalance. embolism and thrombosis. fever. gastrointestinal discomfort. gastrointestinal disorders. genital oedema. haemorrhage. headache. hypersensitivity. hypertension. increased risk of infection. insomnia. lacrimation disorder. mucositis. myalgia. nail disorder. nausea. neutropenia. oedema. oral disorders. pain. paraesthesia. post procedural infection. renal failure. respiratory disorders. scrotal oedema. sepsis. skin reactions. taste altered. thrombocytopenia. vomiting ▶Uncommon Healing impaired. intracranial haemorrhage. pericardial effusion SIDE-EFFECTS, FURTHER INFORMATION Hypersensitivity reactions, including some life-threatening and rare fatal reactions, are associated with temsirolimus therapy. Symptoms include flushing, chest pain, dyspnoea, apnoea, hypotension, loss of consciousness, and anaphylaxis. Patients should receive an intravenous dose of antihistamine 30 minutes before starting the temsirolimus infusion. The infusion may have to be stopped temporarily for the treatment of infusion-related effects—consult product literature for appropriate management. If adverse reactions are not managed with dose delays, a dose reduction should be considered—consult product literature.
PDF page 1080
Ensure effective contraception during treatment in men and women.
PDF page 1080
Manufacturer advises avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1080
Manufacturer advises discontinue breast-feeding.
PDF page 1080
▶When used for Renal cell carcinoma Manufacturer advises caution. ▶When used for Mantle cell lymphoma Manufacturer advises caution in mild impairment; avoid in moderate to severe impairment. Dose adjustments ▶When used for Renal cell carcinoma Manufacturer advises dose reduction in severe impairment—consult product literature.
PDF page 1080
Manufacturer advises caution in severe impairment—no information available.
PDF page 1080
▶Monitor respiratory function. ▶Monitor blood lipids.
PDF page 1080
There can be variation in the licensing of different medicines containing the same drug. Solution for infusion EXCIPIENTS: May contain Ethanol, propylene glycol ▶Torisel (Pfizer Ltd) Temsirolimus 25 mg per 1 ml Torisel 30mg/1.2ml concentrate for solution for infusion vials and diluent | 1 vial P £620.00 (Hospital only)
PDF page 1080
(consult product literature or local protocols)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1080